FFB | Jotup

R.E.A. Holdings plc: Circular re further investment by DSN in REA Kaltim

Retrieved on:

Tuesday, January 30, 2024

Fruit, FFB, ATP, Palm oil, Food, Collection, Mining, KCC, Coal, RSPO, PU, MCU, AP, IPA, Round Table, CPO, Exercise, Sand, Zoological society, Coal mining, Certification, Growth

As is normal, crops were weighted to the second half although, unusually, there was no pronounced peak in the fourth quarter.

Key Points:

As is normal, crops were weighted to the second half although, unusually, there was no pronounced peak in the fourth quarter.
This was likely a consequence of a period of lower rainfall that, while typically occurring each year, fell later than usual in 2023.
The initial output is being utilised to surface the quarry ends of two roads leading from the quarry to the continuing REA Kaltim sub-group's estates.
Debt and cash were increased in November 2023 upon receipt by REA Kaltim of the pre-closing loan of $10.0 million from AP.

FFB Bancorp Earns $7.57 million, or $2.38 per Diluted Share, for Fourth Quarter 2023; Earns $33.56 million, or $10.56 per Diluted Share, for Full Year 2023

Retrieved on:

Wednesday, January 24, 2024

DSCR, FFB, ISO, C&I, Partnership, CRE, Merchant services, Government, Treasury, USDA, Sale, Investment, SBA, Marketing

There was a loss on sale of investments of $1.11 million during the fourth quarter of 2023, compared to a loss of $305,000 during the fourth quarter 2022, and no loss in the linked quarter.

Key Points:

There was a loss on sale of investments of $1.11 million during the fourth quarter of 2023, compared to a loss of $305,000 during the fourth quarter 2022, and no loss in the linked quarter.
During the fourth quarter, we sold $20.17 million in non-agency securities and reinvested the proceeds into higher-yielding agency-backed securities.
Non-interest expense increased 41% to $11.05 million for the fourth quarter of 2023, compared to $7.85 million for the fourth quarter 2022, and increased 11% from $9.97 million for the linked quarter.
Merchant operating expense totaled $1.85 million for the fourth quarter of 2023, compared to $1.02 million for the fourth quarter of 2022 and $1.79 million for the preceding quarter.

Enhancing Palm Oil Competitiveness through ISPO: Scenarios and Recommendations

Retrieved on:

Wednesday, December 20, 2023

FFB, ISPO, Palm oil, ANTARA, Agriculture, Government, Certification

The Indonesian Sustainable Palm Oil (ISPO) scheme, initiated in 2011, seeks to establish sustainability standards.

Key Points:

The Indonesian Sustainable Palm Oil (ISPO) scheme, initiated in 2011, seeks to establish sustainability standards.
The scenarios presented highlight potential market shifts and underscore the importance of proactive measures for the sustainable development of the palm oil industry.
Potential consequences include an emerging illegal market, lower prices for smallholders, and a decline in palm oil market share.
The scenarios presented highlight potential market shifts and underscore the importance of proactive measures for the sustainable development of the palm oil industry.

Implandata Announces Appointment of New Members Dr. Adrienne Graves and Jan Willem de Cler to Join Board of Directors

Retrieved on:

Tuesday, October 24, 2023

HANNOVER, Germany, Oct. 24, 2023 /PRNewswire-PRWeb/ -- A visual scientist by training and a global industry leader in ophthalmology, Dr. Adrienne Graves brings extensive experience to Implandata. As the former CEO of Santen Inc., she successfully established a strong global presence, bringing multiple ophthalmic products through development to approval and commercialization and leading global teams through successful acquisitions and partnerships. Prior to Santen, she spent 9 years at Alcon, joining as Senior Scientist to establish Alcon's first Retinal Electrophysiology Laboratory. She progressed through roles of increasing responsibility in research and development, including directing clinical development in multiple therapeutic areas and serving as Director of International Ophthalmology. Dr. Graves currently serves as a director on the boards of various ophthalmic pharmaceutical and health-tech companies. She serves on the Foundation Boards of the American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology Foundation (Emeritus), Retina Global, Himalayan Cataract Project, Foundation Fighting Blindness (FFB) and the RD (Retinal Degeneration) Fund. Dr. Graves also co-founded Glaucoma 360 and OWL (Ophthalmic World Leaders, formerly Ophthalmic Women Leaders).

Key Points:

Jan Willem de Cler will also take over responsibility as Chairman of the Board.
HANNOVER, Germany, Oct. 24, 2023 /PRNewswire-PRWeb/ -- A visual scientist by training and a global industry leader in ophthalmology, Dr. Adrienne Graves brings extensive experience to Implandata.
Prior to Santen, she spent 9 years at Alcon, joining as Senior Scientist to establish Alcon's first Retinal Electrophysiology Laboratory.
Jan Willem studied Business Administration at Nijenrode University in the Netherlands and the University of Oregon, USA where he accomplished his MBA.

FFB Bancorp Earns $8.87 Million, or $2.79 per Diluted Share, for Third Quarter 2023

Retrieved on:

Wednesday, October 18, 2023

FFB, Sale, OTCQX, Communities First, Environment, Growth, CFO, Natural borrowing limit, Merchant, Investment, ISO, Security (finance), Bank, Video game

Third quarter 2023 results were highlighted by continued net interest margin expansion, which improved 84 basis points to 5.21% at September 30, 2023, from the third quarter of 2022.

Key Points:

Third quarter 2023 results were highlighted by continued net interest margin expansion, which improved 84 basis points to 5.21% at September 30, 2023, from the third quarter of 2022.
Third Quarter 2023 Highlights: As of, or for the quarter ended September 30, 2023, compared to the quarter ended September 30, 2022:
Pre-tax, pre-provision income increased 31% to $12.32 million.
“We delivered stellar earnings for the third quarter 2023, achieving record earnings for the first nine months of 2023,” said Bhavneet Gill, CFO and Acting President & CEO.
The cost of funds was 0.24% for the third quarter a year earlier, and 0.62% for the second quarter of 2023.

FFB Bancorp President and CEO Taking Personal Leave of Absence

Retrieved on:

Monday, September 25, 2023

Senior, Communities First, Sadness, Love, FFB, Family, Breast cancer, Management

FRESNO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- FFB Bancorp, formerly Communities First Financial Corporation (the “Company”) (OTCQX: FFBB), the parent company of FFB Bank (the “Bank”), announced today that Steve Miller, President and Chief Executive Officer, will be taking a temporary leave of absence to be with his spouse and family, effective September 25, 2023.

Key Points:

FRESNO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- FFB Bancorp, formerly Communities First Financial Corporation (the “Company”) (OTCQX: FFBB), the parent company of FFB Bank (the “Bank”), announced today that Steve Miller, President and Chief Executive Officer, will be taking a temporary leave of absence to be with his spouse and family, effective September 25, 2023.
Bhavneet Gill, Executive Vice President and Chief Financial Officer, will step in as the Acting CEO during Steve’s absence and a senior management committee was formed to engage with the Board as needed.
This group consists of the Chief Credit Officer, Chief Operating Officer, and the Chief Marketing/Revenue Officer.
“We have planned and prepared for Steve to take this leave of absence.

AiViva Biopharma Appoints Lester J. Kaplan, PhD to the Board of Directors

Retrieved on:

Monday, September 18, 2023

Executive, Research and development, Drug development, Keck Graduate Institute, United States Air Force Scientific Advisory Board, IP, Doctor of Philosophy, Development, Zaporizhzhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine, Acadia Pharmaceuticals, European, Growth, FFB, UCLA, FDA, Therapy, Management, Allergan, Health

COSTA MESA, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company developing innovative therapies to address major unmet medical needs, today announced the appointment of Dr. Lester J. Kaplan, PhD to its board of directors.

Key Points:

COSTA MESA, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company developing innovative therapies to address major unmet medical needs, today announced the appointment of Dr. Lester J. Kaplan, PhD to its board of directors.
Dr. Kaplan served as the Executive Vice President and President, Research & Development and Global Botox, and a board member of Allergan.
“I am honored and excited to welcome Dr. Kaplan to the board of directors.
Dr. Kaplan’s long history of leadership and deep experience in drug development will be invaluable to AiViva BioPharma,” said Diane Tang-Liu, PhD, President and CEO of AiViva.

Danimer Scientific Invited into Due Diligence and Term Sheet Negotiation Phase for a Federal Financing Bank Loan and DOE Loan Guarantee

Retrieved on:

Tuesday, August 8, 2023

Due Diligence encompasses detailed confirmatory review which may result in term sheet negotiations with the Company.

Key Points:

Due Diligence encompasses detailed confirmatory review which may result in term sheet negotiations with the Company.
If successful, a U.S. Department of the Treasury’s Federal Financing Bank (FFB) loan guaranteed by the DOE would assist funding the Company’s capacity expansion efforts to bring increased volumes of PHA and PHA-based resins to the marketplace.
Completion of Due Diligence could ultimately result in a conditional commitment and final FFB loan guaranteed by the DOE.
The foregoing matters are wholly dependent on the results of the Due Diligence and the LPO’s determination of whether to proceed.

R.E.A. Holdings plc: Trading update

Retrieved on:

Wednesday, August 2, 2023

MAR, Coal, Growth, FFB, CPO, Sand, Rare-earth element

Since the low point in June, the CPO price has rallied and currently stands at $960 per tonne.

Key Points:

Since the low point in June, the CPO price has rallied and currently stands at $960 per tonne.
The average selling price for the group’s CPKO, on the same basis, was $875 per tonne (2022: $1,712 per tonne).
In line with the timetable adopted in previous years, the company’s half yearly report for 2023 will be published in late September 2023.
Dissemination of a Regulatory Announcement that contains inside information in accordance with the Market Abuse Regulation (MAR), transmitted by EQS Group.

FFB Bancorp Earns Record $9.42 Million, or $2.97 per Diluted Share, for Second Quarter 2023

Retrieved on:

Wednesday, July 19, 2023

Natural borrowing limit, ISO, EVP, Merchant, Communities First, Sale, Miller, Investment, Growth, FFB, Ecosystem, Environment, Bank, Security (finance), Video game

Second quarter 2023 results were highlighted by continued net interest margin expansion, which improved to 5.09% at June 30, 2023.

Key Points:

Second quarter 2023 results were highlighted by continued net interest margin expansion, which improved to 5.09% at June 30, 2023.
Second Quarter 2023 Highlights: As of, or for the quarter ended June 30, 2023, compared to the quarter ended June 30, 2022:
Pre-tax, pre-provision income increased 59% to $13.81 million.
The yield on earning assets was 5.75% for the second quarter of 2023, compared to 4.37% for the second quarter a year ago, and 5.59% on a linked quarter basis.
Total non-interest income was $8.12 million for the second quarter of 2023, compared to $4.24 million for the second quarter of 2022, and $4.56 million for the preceding quarter.